Knight Therapeutics raises 2026 revenue outlook to $540 million-$560 million

Second-quarter revenue rose 34% to $144.2 million as promoted products expanded, adjusted EBITDA climbed 58%, and the company repaid the revolving credit facility used for the Paladin transaction.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.